Global Polio Vaccines Market to Reach USD 1.4 Billion by 2034, Growing at 5.0% CAGR

The global polio vaccines market was valued at USD 794.1 million in 2023 and is projected to reach USD 1.4 billion by the end of 2034, reflecting steady expansion over the forecast period. The market is expected to grow at a CAGR of 5.0% from 2024 to 2034, driven by ongoing global immunization programs, strong support from government and international health organizations, and continued efforts toward polio eradication, particularly in developing regions.

Governments' favorable policies regarding the eradication of polio are the factors responsible for the polio vaccines market growth. The polio eradication programs are being conducted on a larger scale worldwide. Though Pakistan and Afghanistan are still struggling with polio, the UNICEF's guidelines regarding polio vaccination are being adhered to in the rest of the parts of the world.

Transform Your Strategy: Explore In-Depth Data - Sample Available! https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86358

Polio vaccines are categorized into a weakened poliovirus administered orally (called oral polio vaccine (OPV)) and an inactivated poliovirus (IPV) that can be injected into the body. The CDC recommends that every child be protected against polio/poliomyelitis as part of a series of the routine childhood vaccines.
IPV is the only vaccine given all over the U.S. since the year 2000. The oral polio vaccine is used in other countries.

Market Segmentation

By Service Type

• Public Healthcare Services: Dominates the market share (~65%). These services facilitate mass immunization days (NIDs) and government-mandated routine childhood schedules.

• Private Healthcare Services: Predicted to witness the highest CAGR as middle-class populations in emerging economies opt for "painless" (IPV-based) combination vaccines in private clinics.

By Sourcing Type

• Tender-Based Procurement: The primary mode for GAVI-supported and UNICEF-led initiatives, which procure billions of doses annually.

• Direct Purchase/Retail: Common in high-income regions and private pediatric practices where vaccines are sourced directly from manufacturers or distributors.

By Application

• Routine Immunization: Accounts for nearly 60% of market revenue, providing the baseline demand for birth doses and pediatric boosters.

• Outbreak Response: A volatile but significant segment, particularly in 2025-2026, as regions like Gaza and Sub-Saharan Africa utilize the nOPV2 for emergency campaigns.

By Industry Vertical

• Hospitals & Clinics: The primary end-users for vaccine administration and storage.

• Government & Public Health Agencies: The strategic "brains" of the market, responsible for national policy and bulk funding.

• NGOs & International Organizations: Key players in fragile states and conflict zones where government infrastructure is lacking.

By Region

• North America: The largest market by value, driven by high per-capita costs and a total reliance on IPV.

• Asia-Pacific: The fastest-growing region due to high birth rates and massive national programs like India's Universal Immunization Programme (UIP).

Regional Analysis

• North America: Remains the dominant force through 2034. The U.S. and Canada prioritize 100% IPV coverage, often utilizing hexavalent combinations that bundle polio with DTaP and HepB.

• Asia-Pacific: Poised for rapid growth. India, Indonesia, and China are scaling up domestic production. For instance, Indonesia's Bio Farma is the sole prequalified producer of nOPV2 as of 2025, making the region a global supply hub.

• Africa: Represents the largest volume demand for OPV. Recent initiatives, such as the 2024-2025 campaigns in Gaza and various African nations, highlight the region's role as the primary "battleground" for eradication.

Market Drivers and Challenges

Drivers

• Eradication Initiatives: Support from the WHO and GPEI ensures a constant floor for demand.

• Technological Progress: The development of nOPV2 (novel Oral Polio Vaccine) has reduced the risk of vaccine-derived outbreaks.

• Combination Vaccines: The rise of Hexavalent vaccines (6-in-1) simplifies the cold chain and improves compliance, boosting IPV volumes.

Challenges

• Supply Chain Gaps: UNICEF tenders in 2025-2026 have seen supply shortfalls (e.g., seeking 120M doses but receiving offers for only 95M), leading to spot price increases of 15-20%.

• Cold-Chain Fragility: In regions like Nigeria and DRC, grid failures can cause up to 22% vaccine wastage, inflating the effective cost per dose.

Market Trends

1. AI Integration: Artificial Intelligence is being used to predict outbreak patterns and optimize delivery to underserved areas, minimizing waste.

2. Vaccine Sovereignty: There is a growing movement toward "local for local" production, exemplified by the Sanofi-Biovac collaboration to produce IPV in Africa.

3. The "Second Dose" Shift: By 2025, 84% of WHO member states have incorporated a second IPV dose into their schedules, doubling the per-capita requirement in many developing markets.

Future Outlook (2034)

By 2034, the market is expected to reach a "post-eradication" readiness phase. This will involve a total phase-out of traditional OPV in favour of IPV and stabilized nOPV strains. High-income markets will likely transition toward needle-free delivery technologies and even more complex combination vaccines to maintain high coverage rates.

Elevate Your Business Strategy! Purchase the Report for Market-Driven Insights: https://www.transparencymarketresearch.com/checkout.php?rep_id=86358<ype=S

Competitive Landscape

The market is characterized by a "medium" level of concentration. Key players include:

• Sanofi S.A.
• GSK plc
• Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL)
• Serum Institute of India
• Panacea Biotec
• Beijing Tiantan Biological Products Corp
• Bio-Med Healthcare Products Pvt. Ltd.
• Halffkine Bio-Pharmaceuticals
• Sinovac Biotech Ltd.
• Pfizer Inc.

Recent Developments

• In June 2024, Sanofi announced that it had entered into collaboration with Biovac to produce inactivated polio vaccines (IPV) in Africa.

• In January 2024, the United Nations children's Fund (UNICEF) announced that it had delivered 340,000 doses of oral polio vaccine (OPV) to Ukraine.
Frequently Asked Questions

• How big was the global polio vaccines market in 2023?

It was valued at US$ 794.1 Mn in 2023

• How is the polio vaccines business expected to grow during the forecast period?

It is projected to grow at a CAGR of 5.0% from 2024 to 2034

• What are the key factors driving the demand for polio vaccines?

Conducive government policies and increase in the number of polio eradication activities

• Which polio vaccines end-user segment held the largest share in 2023?

Hospitals & clinics held the largest share in 2023.

• Which region dominated the global polio vaccines landscape in 2023?

North America was the dominant region in 2023

• Who are the key polio vaccines industry manufacturers?

Sanofi S.A., GSK plc, Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL), Serum Institute of India, Panacea Biotec, Beijing Tiantan Biological Products Corp, Bio-Med Healthcare Products Pvt. Ltd. Halffkine Bio-Pharmaceuticals, Sinovac Biotech Ltd., and Pfizer Inc.

Explore Latest Research Reports by Transparency Market Research:

Skin Antiseptic Market - https://www.transparencymarketresearch.com/skin-antiseptic-market.html

Medical Devices Outsourcing Market -
https://www.transparencymarketresearch.com/medical-devices-outsourcing-market.html

Microscopy Devices Market - https://www.transparencymarketresearch.com/microscopy-market.html

Autoinjectors Market - https://www.transparencymarketresearch.com/autoinjectors-market.html

Dental 3D Printing Market - https://www.transparencymarketresearch.com/dental-3d-printer-market.html

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com

This release was published on openPR.